- Home
- SNDX
as 03-25-2025 11:39am EST
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.2B | IPO Year: | 2016 |
| Target Price: | $36.20 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.06 - $25.07 | Next Earning Date: | 03-03-2025 |
| Revenue: | $23,680,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 274.86% | Revenue Growth (next year): | 130.47% |
Stock Insider Trading Activity of Syndax Pharmaceuticals Inc. (SNDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Metzger Michael A | SNDX | Chief Executive Officer | Mar 4 '25 | Sell | $15.05 | 7,814 | $117,563.97 | 300,121 | |
| Gallagher Neil | SNDX | President, Head of R&D | Feb 10 '25 | Sell | $15.50 | 4,618 | $71,597.47 | 85,095 | |
| Goldan Keith A. | SNDX | Chief Financial Officer | Feb 10 '25 | Sell | $15.50 | 3,777 | $58,558.61 | 90,746 | |
| Metzger Michael A | SNDX | Chief Executive Officer | Feb 10 '25 | Sell | $15.50 | 13,288 | $206,017.15 | 300,121 |
Latest Syndax Pharmaceuticals Inc. News
SNDX Breaking Stock News: Dive into SNDX Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 days ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GuruFocus.com
21 days ago
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...
MT Newswires
22 days ago
B. Riley Cuts Price Target on Syndax Pharmaceuticals to $29 From $36, Keeps Buy Rating
Zacks
23 days ago
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates
MT Newswires
23 days ago
Syndax Pharmaceuticals Q4 Loss Widens
Associated Press Finance
23 days ago
Syndax: Q4 Earnings Snapshot
GlobeNewswire
23 days ago
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GuruFocus.com
a month ago
Earnings To Watch: Syndax Pharmaceuticals Inc (SNDX) Reports Q4 2024 Result
Compare SNDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNDX Syndax Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.